Hoth: Positive Preclinical Results of HT-ALZ treatment for Alzheimer's

 Higher Dosing Shows Positive Effects on Cognitive Function

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical  company, today announced that HT-ALZ a therapeutic in development for the treatment of Alzheimer's disease achieved positive preclinical results that outpaced its pervious study.  In particular, the higher dose appears to be most beneficial in a spatial memory test performed at Washington University in St Louis.

Hoth has now completed the behavior results for Locomotor Activity/Exploratory Behavior, Elevated Plus Maze, Spatial Navigation Water Maze, Prepulse Inhibition of Startle, and Conditioned Fear and looks forward to sharing further data as it becomes available.

https://www.biospace.com/article/releases/hoth-therapeutics-announces-positive-preclinical-results-of-ht-alz-treatment-for-alzheimer-s-disease/